Which should be added to cisplatin for advanced non-small-cell lung cancer—vinorelbine or gemcitabine?
Giorgio V Scagliotti
Correspondence University of Turin, Department of Clinical and Biological Sciences Head, Thoracic Oncology Unit, S. Luigi Hospital—Regione, Gonzole 10, 10043 Orbassano (Torino), Italy.
Email giorgio.scagliotti@unito.it
This article has no abstract so we have provided the first paragraph of the full text.
Cisplatin-based chemotherapy has a proven role in the management of locally advanced and metastatic NSCLC and its superiority versus best supportive care is no longer in question.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.